The upgrade from Morgan Stanley is a positive signal for NeuroPace. The change from Underweight to Equal-Weight indicates a more favorable view of the company's stock, and the increase in price target suggests that the analyst sees potential for the stock's price to rise. This could lead to increased investor interest and potentially a short-term increase in stock price.